默克-话题@MedSci

#默克#

100篇内容 | 3137人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273949, encodeId=075112e3949ac, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, objectType=article, longId=201991, objectId=5d832019917b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d832019917b, replyNumber=0, likeNumber=73, createdTime=2020-10-13, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d832019917b, moduleTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d832019917b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273948, encodeId=04ea12e394869, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, objectType=article, longId=199750, objectId=6fb7199e501c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb7199e501c, replyNumber=0, likeNumber=63, createdTime=2020-08-22, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb7199e501c, moduleTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb7199e501c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273947, encodeId=e6ea12e394751, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, objectType=article, longId=195619, objectId=fa0e195619b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa0e195619b6, replyNumber=0, likeNumber=66, createdTime=2020-06-12, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa0e195619b6, moduleTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa0e195619b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273946, encodeId=a66312e39467d, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克携两款候选疫苗加入COVID-19疫苗竞赛, objectType=article, longId=194854, objectId=63d01948541e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63d01948541e, replyNumber=0, likeNumber=82, createdTime=2020-05-29, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63d01948541e, moduleTitle=默克携两款候选疫苗加入COVID-19疫苗竞赛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63d01948541e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273945, encodeId=1cc212e39453f, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌, objectType=article, longId=194609, objectId=150b19460996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=150b19460996, replyNumber=0, likeNumber=61, createdTime=2020-05-24, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=150b19460996, moduleTitle=FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=150b19460996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273944, encodeId=12c412e3944d1, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, objectType=article, longId=193319, objectId=6adc193319bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6adc193319bd, replyNumber=0, likeNumber=73, createdTime=2020-05-03, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6adc193319bd, moduleTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6adc193319bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273943, encodeId=2dd212e3943d8, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, objectType=article, longId=192958, objectId=e2db19295879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2db19295879, replyNumber=0, likeNumber=48, createdTime=2020-04-27, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2db19295879, moduleTitle=阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2db19295879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273942, encodeId=fa5912e3942c2, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%, objectType=article, longId=192587, objectId=6b7419258e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7419258e79, replyNumber=0, likeNumber=72, createdTime=2020-04-22, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7419258e79, moduleTitle=JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b7419258e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273941, encodeId=f4d412e39414e, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛, objectType=article, longId=191859, objectId=6d7f19185941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7f19185941, replyNumber=0, likeNumber=88, createdTime=2020-04-11, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7f19185941, moduleTitle=FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7f19185941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273940, encodeId=c8f712e3940a5, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克的PD-1单抗Keytruda：一线治疗结肠直肠癌优于化学疗法, objectType=article, longId=191474, objectId=78ce1914e4eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78ce1914e4eb, replyNumber=0, likeNumber=55, createdTime=2020-04-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78ce1914e4eb, moduleTitle=默克的PD-1单抗Keytruda：一线治疗结肠直肠癌优于化学疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78ce1914e4eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273939, encodeId=63e512e393918, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克公司的埃博拉疫苗Ervebo在四个非洲国家获得批准, objectType=article, longId=188483, objectId=16e7188483ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16e7188483ae, replyNumber=0, likeNumber=86, createdTime=2020-02-22, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16e7188483ae, moduleTitle=默克公司的埃博拉疫苗Ervebo在四个非洲国家获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16e7188483ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273938, encodeId=c18e12e3938d9, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克向FDA申请，将Belsomra用于治疗阿尔茨海默氏症患者的睡眠障碍, objectType=article, longId=187479, objectId=318b18e47983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=318b18e47983, replyNumber=0, likeNumber=67, createdTime=2020-02-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=318b18e47983, moduleTitle=默克向FDA申请，将Belsomra用于治疗阿尔茨海默氏症患者的睡眠障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=318b18e47983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273937, encodeId=7f6d12e393732, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克针对革兰氏阴性菌感染的抗生素组合Recarbrio，获得FDA的优先审查, objectType=article, longId=187478, objectId=ab9e18e47852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab9e18e47852, replyNumber=0, likeNumber=100, createdTime=2020-02-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab9e18e47852, moduleTitle=默克针对革兰氏阴性菌感染的抗生素组合Recarbrio，获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab9e18e47852)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273936, encodeId=900412e3936a2, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克的Keytruda成为美国批准用于治疗非肌肉浸润性膀胱癌的抗PD-1治疗药物, objectType=article, longId=185986, objectId=24e318598641, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24e318598641, replyNumber=0, likeNumber=66, createdTime=2020-01-11, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24e318598641, moduleTitle=默克的Keytruda成为美国批准用于治疗非肌肉浸润性膀胱癌的抗PD-1治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24e318598641)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273935, encodeId=78d712e3935b2, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=62, createdTime=2020-01-08, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273934, encodeId=477912e393434, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=美国批准默克的埃博拉病毒预防疫苗上市, objectType=article, longId=185144, objectId=d51218514423, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d51218514423, replyNumber=0, likeNumber=72, createdTime=2019-12-26, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d51218514423, moduleTitle=美国批准默克的埃博拉病毒预防疫苗上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d51218514423)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273933, encodeId=0e5412e3933a6, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗, objectType=article, longId=184954, objectId=668a18495452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=668a18495452, replyNumber=0, likeNumber=71, createdTime=2019-12-21, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=668a18495452, moduleTitle=阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=668a18495452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273932, encodeId=990612e39327b, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=阿斯利康/默克的PARP抑制剂Lynparza在中国获准用作卵巢癌的一线治疗, objectType=article, longId=184297, objectId=a8b018429e5e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b018429e5e, replyNumber=0, likeNumber=59, createdTime=2019-12-08, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b018429e5e, moduleTitle=阿斯利康/默克的PARP抑制剂Lynparza在中国获准用作卵巢癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b018429e5e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273931, encodeId=bd0112e3931d7, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=NEJM：默克尔细胞癌-病例报道, objectType=article, longId=184212, objectId=59161842124f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59161842124f, replyNumber=0, likeNumber=73, createdTime=2019-12-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59161842124f, moduleTitle=NEJM：默克尔细胞癌-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59161842124f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273930, encodeId=bfe512e3930eb, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克与平安好医生达成战略合作，推进中国智慧医疗发展, objectType=article, longId=184194, objectId=0c4e1841940b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c4e1841940b, replyNumber=0, likeNumber=70, createdTime=2019-12-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c4e1841940b, moduleTitle=默克与平安好医生达成战略合作，推进中国智慧医疗发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c4e1841940b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

默克

2020-05-29

makuansheng (审核中...)

前往app查看评论内容

#默克#

靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华

2020-10-13

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期

2020-08-22

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败

2020-06-12

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克携两款候选疫苗加入COVID-19疫苗竞赛

2020-05-29

makuansheng (审核中...)

前往app查看评论内容

#默克#

FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌

2020-05-24

makuansheng (审核中...)

前往app查看评论内容

#默克#

FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率

2020-05-03

makuansheng (审核中...)

前往app查看评论内容

#默克#

阿斯利康/默克的PARP抑制剂Lynparza延长了转移性去势抵抗性前列腺癌男性的生存期

2020-04-27

makuansheng (审核中...)

前往app查看评论内容

#默克#

JTO：默克PD-L1双特异性抗体显神威，1期结果显示在NSCLC的ORR可达36%

2020-04-22

makuansheng (审核中...)

前往app查看评论内容

#默克#

FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛

2020-04-11

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克的PD-1单抗Keytruda：一线治疗结肠直肠癌优于化学疗法

2020-04-06

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克公司的埃博拉疫苗Ervebo在四个非洲国家获得批准

2020-02-22

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克向FDA申请，将Belsomra用于治疗阿尔茨海默氏症患者的睡眠障碍

2020-02-06

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克针对革兰氏阴性菌感染的抗生素组合Recarbrio，获得FDA的优先审查

2020-02-06

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克的Keytruda成为美国批准用于治疗非肌肉浸润性膀胱癌的抗PD-1治疗药物

2020-01-11

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-01-08

makuansheng (审核中...)

前往app查看评论内容

#默克#

美国批准默克的埃博拉病毒预防疫苗上市

2019-12-26

makuansheng (审核中...)

前往app查看评论内容

#默克#

阿斯利康和默克的PARP抑制剂Lynparza获FDA批准,用作晚期胰腺癌的维持治疗

2019-12-21

makuansheng (审核中...)

前往app查看评论内容

#默克#

阿斯利康/默克的PARP抑制剂Lynparza在中国获准用作卵巢癌的一线治疗

2019-12-08

makuansheng (审核中...)

前往app查看评论内容

#默克#

NEJM：默克尔细胞癌-病例报道

2019-12-06

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克与平安好医生达成战略合作，推进中国智慧医疗发展

2019-12-06

科室
- - 订阅+
  - 更多科室
工具
服务